Nemolizumab for Lichen Planopilaris

This trial tests nemolizumab, a medication typically used for conditions like eczema, to determine its effectiveness for lichen planopilaris (LPP), which causes permanent hair loss and scalp itching. Researchers seek new treatments because current options often prove ineffective or cause side effects. Individuals diagnosed with LPP and experiencing frequent scalp itching might be suitable for this trial. Participants will receive nemolizumab injections every four weeks. As a Phase 4 trial, this study involves an FDA-approved treatment and aims to understand how it can benefit more patients with LPP.

You may need to stop certain medications before joining the trial. If you're using JAK inhibitors, biologics, DMARDs, or corticosteroids, you must stop them for at least 12 weeks (for JAK inhibitors, biologics, and DMARDs) or 4 weeks (for corticosteroids) before starting the trial. Other hair loss treatments must be stable for 6 months or stopped for 3 months.

Studies have shown that nemolizumab is generally safe. Research on its use for conditions like prurigo nodularis and atopic dermatitis indicates that patients tolerate nemolizumab well. Most side effects are mild, with some experiencing skin reactions such as redness or itchiness at the injection site. In one study, 39.5% of patients reported side effects, mostly related to the skin and not severe.

Most treatments for lichen planopilaris involve corticosteroids or immunosuppressants to reduce inflammation and slow disease progression. However, nemolizumab is unique because it targets the IL-31 receptor, which is involved in the itch and inflammation process of this condition. By blocking this receptor, nemolizumab may provide relief from symptoms with potentially fewer side effects compared to traditional immunosuppressants. Researchers are excited about nemolizumab as it offers a new mechanism of action that could improve patient outcomes and quality of life.

Research has shown that nemolizumab works well for conditions causing itching and thickened skin. It is approved for treating prurigo nodularis and atopic dermatitis, where it reduces itching and improves skin health. In studies, patients using nemolizumab were more than three times as likely to experience significant itch relief. This trial will evaluate nemolizumab as a promising option for lichen planopilaris, a condition that leads to hair loss and an itchy scalp. Its success in similar conditions suggests it might effectively manage symptoms of lichen planopilaris.¹²⁵⁶⁷